Amicus Therapeutics v. Teva Pharmaceuticals: Migalastat ANDA Consent Judgment
Amicus Therapeutics asserted 23 patents covering migalastat — a rare-disease therapy for Fabry disease — against Teva’s ANDA filing in Delaware District Court. The case resolved after 717 days via consent judgment: Teva acknowledged infringement and validity, accepted a permanent injunction, and entered a license agreement with Amicus.
23-patent ANDA battle over Fabry disease drug ends in injunction and licence
Amicus Therapeutics US LLC and Amicus Therapeutics Inc. filed suit on 7 November 2022 in the District of Delaware against Teva Pharmaceutical Industries Ltd., Teva Pharmaceuticals Inc., and Teva Pharmaceuticals USA Inc., asserting 23 US patents covering migalastat — a pharmacological chaperone therapy marketed for Fabry disease, including methods of treating patients with renal impairment and use in pregnant patients. The action arose under the Hatch-Waxman Act following Teva’s submission of ANDA No. 217586, which constituted a constructive act of infringement under 35 U.S.C. § 271(e)(2).
The case closed on 24 October 2024 via a consent judgment and permanent injunction. Teva formally acknowledged Amicus’s ownership, standing, and the validity and enforceability of the asserted patents. Teva also acknowledged infringement of all asserted patents and accepted a permanent injunction barring commercial manufacture, use, sale, importation, or distribution of any generic migalastat product covered by its ANDA, except under a licence granted by Amicus. Simultaneously, the parties entered a license agreement governing Teva’s future rights, and all claims were dismissed without prejudice.
The 717-day duration is consistent with contested Hatch-Waxman proceedings that approach or reach full briefing before settlement negotiations succeed. The simultaneous entry of a permanent injunction, a licence, and dismissal without prejudice is a structurally common resolution in ANDA litigation: it protects the brand’s market exclusivity while giving the generic a defined commercialisation pathway. The precise financial terms of the licence, including any royalty rate, milestone payments, or authorised-generic arrangements, are not disclosed in the public record and may remain confidential.
Filing to Consent Judgment in 717 days
717 days to resolution — broadly consistent with ANDA Hatch-Waxman consent timelines in Delaware
Consent judgment decoded: what the permanent injunction and licence mean for both parties
Consent judgment combines injunction with licence — a structured ANDA exit
A consent judgment in ANDA litigation is a negotiated court order carrying the force of a final judgment without a full trial. Here, Teva stipulated to infringement and validity, and the court entered a permanent injunction. Crucially, the judgment also references a licence agreement — meaning Teva retains a defined, contractually controlled route to market, while Amicus secures binding court-level enforcement authority. The dismissal without prejudice preserves the ability to return to court if the licence terms are breached.
Hatch-Waxman consent decreeAmicus secures validity acknowledgment and injunctive protection across all 23 patents
For Amicus, the outcome is strategically strong. Teva’s acknowledgment of validity and enforceability across 23 patents creates a robust public record that may deter further ANDA filers from mounting paragraph IV challenges. The permanent injunction blocks unauthorised generic entry, and the licence agreement allows Amicus to control the timing and economics of any generic launch. The court retains jurisdiction over licence enforcement, giving Amicus an expedited enforcement mechanism if Teva deviates from licence terms.
Amicus: injunction + licence control securedTeva trades ANDA independence for a licensed market-entry pathway
Teva acknowledged infringement and accepted a permanent injunction — a significant concession. However, the simultaneous execution of a licence agreement suggests Teva secured a defined commercial pathway rather than an indefinite bar. Generic companies routinely accept consent judgments in ANDA cases when a negotiated launch date or royalty structure provides more certainty than continued litigation risk. The specific launch date, royalty terms, and any authorised-generic arrangements remain undisclosed in the public record.
Teva: licensed entry, no unauthorised launch23-patent portfolio creates high barrier for future Fabry disease generic challengers
The breadth of Amicus’s asserted portfolio — 23 patents spanning formulation, dosing in renal impairment, and use in pregnancy — signals a dense IP thicket around migalastat. Teva’s public acknowledgment of validity across all asserted patents may discourage subsequent ANDA filers from asserting paragraph IV certifications without compelling distinguishing arguments. For the rare-disease pharmaceutical sector, this outcome reinforces the value of layered patent strategies combining composition, method-of-treatment, and patient-population claims.
High portfolio barrier; rare disease IP precedentFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Amicus Therapeutics US, LLC | Company | Rare-disease biopharmaceutical company — holder of 23 migalastat patents for Fabry diseaseSearch in Eureka ↗ |
| Co-Plaintiff | Amicus Therapeutics, Inc. | Company | Search in Eureka ↗ |
| Defendant | Teva Pharmaceutical Industries, Ltd. | Company | Generic pharmaceutical manufacturer that filed ANDA No. 217586 seeking approval of generic migalastatSearch in Eureka ↗ |
| Co-Defendant | Teva pharmaceuticals, Inc. | Company | Search in Eureka ↗ |
| Co-Defendant | Teva Pharmaceuticals USA, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Anna Whitacre | Attorney | Counsel for Amicus Therapeutics US, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Chad S.C. Stover | Attorney | Counsel for Amicus Therapeutics US, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Christina M. Baugh | Attorney | Counsel for Amicus Therapeutics US, LLCSearch in Eureka ↗ |
| Plaintiff counsel | John W. Cox | Attorney | Counsel for Amicus Therapeutics US, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Joshua E. Ney | Attorney | Counsel for Amicus Therapeutics US, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Joshua M. Kalb | Attorney | Counsel for Amicus Therapeutics US, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Lauren Baker | Attorney | Counsel for Amicus Therapeutics US, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Mark C. Nelson | Attorney | Counsel for Amicus Therapeutics US, LLCSearch in Eureka ↗ |
| Plaintiff law firm | Barnes & Thornburg, LLP | Law Firm | Representing Amicus Therapeutics US, LLCSearch in Eureka ↗ |
| Defendant counsel | Nathan Roger Hoeschen | Attorney | Counsel for Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Defendant law firm | Shaw Keller LLP | Law Firm | Representing Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Presiding judge | Judge Christopher J. Burke | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The consent judgment is notable for its explicit enumeration of Teva’s concessions: acknowledgment of Amicus’s ownership and standing, validity and enforceability of all 23 asserted patents, and infringement under 35 U.S.C. § 271(e)(2). The permanent injunction covers not only direct infringement but also inducement and contributory infringement — foreclosing indirect pathways to market. The carve-out for products supplied ‘pursuant to a licence granted by Amicus’ confirms a contemporaneous licence agreement controls the commercial relationship. The dismissal without prejudice, combined with retained jurisdiction, provides Amicus with a rapid return-to-court mechanism. The mutual cost-bearing provision is consistent with a negotiated outcome rather than one imposed after contested proceedings.
US11278539B2 and 22 further patents — migalastat formulations and Fabry disease treatment methods
The 23 asserted patents cover migalastat (also known by brand name Galafold), a first-in-class oral pharmacological chaperone approved for the treatment of Fabry disease — a rare X-linked lysosomal storage disorder caused by mutations in the GLA gene encoding alpha-galactosidase A. The patents span multiple dimensions of the product’s clinical use: core formulation and composition claims, dosing regimens, and critically, method-of-treatment claims directed at specific patient sub-populations including those with renal impairment and pregnant patients. Application dates cluster around 2019–2022, reflecting a lifecycle management strategy layering new clinical data into additional patent protection.
The breadth of this portfolio — 23 patents across formulation, dosing, and patient-population axes — represents a deliberate and commercially significant rare-disease IP strategy. For competitors and ANDA filers, no single invalidity argument can clear the entire thicket; each patent family requires independent analysis. For in-house IP teams at rare-disease companies, Amicus’s approach illustrates how clinical trial sub-populations and real-world evidence (renal impairment outcomes, pregnancy safety data) can be converted into distinct patent claims that materially extend effective exclusivity beyond the primary composition patent expiry.
Should you run an FTO against migalastat and the Amicus patent portfolio?
Any company developing a generic, biosimilar, or next-generation pharmacological chaperone for Fabry disease — or any alpha-galactosidase A enzyme replacement or chaperone therapy — should conduct a thorough FTO review against Amicus’s 23-patent portfolio. The portfolio covers not just the core migalastat molecule but dosing methods and patient sub-populations, meaning even a reformulated or differently dosed product may fall within claim scope. ANDA filers and product teams in Fabry disease and related lysosomal storage disorders face particular exposure given the density and recency of these patents.
PatSnap Eureka’s FTO Search Agent enables IP teams to map all 23 Amicus patents against a candidate compound’s proposed label, dosing regimen, and target patient population simultaneously. Eureka surfaces claim-level overlap, identifies design-around opportunities, and tracks continuation applications that may add further claims to existing families — critical intelligence for rare-disease generic developers operating under Hatch-Waxman timelines.
Run a freedom-to-operate analysis on US11278539B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA patent cases involving rare-disease and orphan drug portfolios
Cases involving Hatch-Waxman ANDA assertions over rare-disease pharmacological chaperone and lysosomal storage disorder therapies in Delaware District Court.
What this case signals for the rare-disease pharmaceutical IP landscape
A 23-patent consent judgment covering Fabry disease therapy offers durable lessons for ANDA strategy, portfolio construction, and FTO in speciality pharma.
Dense ANDA patent portfolios materially raise the cost of generic entry
Amicus’s 23-patent assertion required Teva to challenge every claim across formulation, dosing regimen, and patient-population patents. Rare-disease sponsors that build layered portfolios covering multiple clinical sub-populations — renal impairment, pregnancy — create litigation economics that push generics toward negotiated licences rather than full invalidity trials.
Consent judgments with retained jurisdiction are stronger than settlement alone
By structuring resolution as a court-entered consent judgment rather than a private settlement, Amicus secured a mechanism to return to the Delaware court if Teva breaches licence terms — without re-filing. Patent holders in ANDA disputes should evaluate whether a consent decree structure, rather than a stipulated dismissal, better protects post-resolution enforcement rights.
Amicus v Teva — key questions answered
The case resolved on 24 October 2024 via a consent judgment and permanent injunction. Teva acknowledged infringement, and the validity and enforceability of all 23 asserted migalastat patents. A permanent injunction was entered blocking unauthorised generic migalastat sales, and the parties simultaneously entered a licence agreement. All claims were dismissed without prejudice. Each party bears its own costs.
Amicus asserted 23 US patents across formulation, dosing, and patient-population dimensions, including methods of treating Fabry patients with renal impairment and use of migalastat in pregnant patients. The breadth of the portfolio — spanning multiple independent patent families — made a blanket invalidity defence strategically challenging for Teva.
Teva’s public acknowledgment of validity and enforceability across 23 patents creates a significant public record that may increase the cost and risk calculus for subsequent ANDA filers. While the acknowledgment is binding only on Teva and does not formally estop other parties, it signals the portfolio’s resilience and may discourage paragraph IV certifications without strong distinguishing arguments.
Migalastat (Galafold) is an oral pharmacological chaperone approved for Fabry disease, a rare lysosomal storage disorder. The 23-patent portfolio reflects a lifecycle management strategy: beyond the core composition claims, Amicus filed patents covering dosing regimens and clinical sub-populations (renal impairment, pregnancy) identified through post-approval clinical data, layering protection across multiple patent expiry dates.
Yes. The consent judgment expressly references a licence agreement between Amicus and Teva governing authorised use of migalastat. The permanent injunction contains a carve-out for products supplied pursuant to a licence granted by Amicus. The specific financial terms — royalty rates, launch date, or authorised-generic provisions — are not disclosed in the public court record.
PatSnap Eureka searches patents and litigation data to answer instantly.